-
1
-
-
84879373604
-
Treatment of acute myeloid leukemia: Are we making progress?
-
Burnett AK: Treatment of acute myeloid leukemia: Are we making progress? Hematology Am Soc Hematol Educ Program 1-6, 2012
-
(2012)
Hematology Am Soc Hematol Educ Program
, pp. 1-6
-
-
Burnett, A.K.1
-
2
-
-
84867608512
-
Acute Myeloid Leukemia (AML): Different treatment strategies versus a common standard arm - Combined prospective analysis by the German AML intergroup
-
Büchner T, Schlenk RF, Schaich M, et al: Acute Myeloid Leukemia (AML): Different treatment strategies versus a common standard arm - Combined prospective analysis by the German AML intergroup. J Clin Oncol 30:3604-3610, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 3604-3610
-
-
Büchner, T.1
Schlenk, R.F.2
Schaich, M.3
-
3
-
-
70349467775
-
Anthracycline dose intensification in acute myeloid leukemia
-
Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259, 2009
-
(2009)
N Engl J Med
, vol.361
, pp. 1249-1259
-
-
Fernandez, H.F.1
Sun, Z.2
Yao, X.3
-
4
-
-
77955914238
-
Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
-
Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
-
(2010)
Blood
, vol.116
, pp. 354-365
-
-
Grimwade, D.1
Hills, R.K.2
Moorman, A.V.3
-
5
-
-
78049502442
-
Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A
-
Schlenk RF, Döhner K, Mack S, et al: Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28:4642-4648, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 4642-4648
-
-
Schlenk, R.F.1
Döhner, K.2
Mack, S.3
-
6
-
-
79959959049
-
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: Landmark analysis from a single prospective multicenter trial
-
Stelljes M, Beelen DW, Braess J, et al: Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: Landmark analysis from a single prospective multicenter trial. Haematologica 96:972-979, 2011
-
(2011)
Haematologica
, vol.96
, pp. 972-979
-
-
Stelljes, M.1
Beelen, D.W.2
Braess, J.3
-
7
-
-
84867099700
-
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach
-
Cornelissen JJ, Gratwohl A, Schlenk RF, et al: The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol 9:579-590, 2012
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 579-590
-
-
Cornelissen, J.J.1
Gratwohl, A.2
Schlenk, R.F.3
-
8
-
-
84876089241
-
If at first you don't succeed: Stem-cell transplantation for acute myeloid leukemia after first relapse
-
Schiffer CA: If at first you don't succeed: Stem-cell transplantation for acute myeloid leukemia after first relapse. J Clin Oncol 31:1259-1261, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 1259-1261
-
-
Schiffer, C.A.1
-
9
-
-
84876095248
-
Acute myeloid leukemia in first remission: To choose transplantation or not?
-
Stone RM: Acute myeloid leukemia in first remission: To choose transplantation or not? J Clin Oncol 31:1262-1266, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 1262-1266
-
-
Stone, R.M.1
-
10
-
-
34247325560
-
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom?
-
DOI 10.1182/blood-2006-06-025627
-
Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109:3658-3666, 2007 (Pubitemid 46641712)
-
(2007)
Blood
, vol.109
, Issue.9
, pp. 3658-3666
-
-
Cornelissen, J.J.1
Van Putten, W.L.J.2
Verdonck, L.F.3
Theobald, M.4
Jacky, E.5
Daenen, S.M.G.6
Van Marwijk, K.M.7
Wijermans, P.8
Schouten, H.9
Huijgens, P.C.10
Van Der, L.H.11
Fey, M.12
Ferrant, A.13
Maertens, J.14
Gratwohl, A.15
Lowenberg, B.16
-
11
-
-
42949142189
-
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
-
DOI 10.1056/NEJMoa074306
-
Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008 (Pubitemid 351620111)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.18
, pp. 1909-1918
-
-
Schlenk, R.F.1
Dohner, K.2
Krauter, J.3
Frohling, S.4
Corbacioglu, A.5
Bullinger, L.6
Habdank, M.7
Spath, D.8
Morgan, M.9
Benner, A.10
Schlegelberger, B.11
Heil, G.12
Ganser, A.13
Dohner, H.14
-
12
-
-
67049164836
-
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials
-
Koreth J, Schlenk R, Kopecky KJ, et al: Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009
-
(2009)
JAMA
, vol.301
, pp. 2349-2361
-
-
Koreth, J.1
Schlenk, R.2
Kopecky, K.J.3
-
13
-
-
49249095034
-
Cytogenetically normal acute myeloid leukemia
-
author reply, 652-653
-
Buchner T, Berdel WE, Kienast J: Cytogenetically normal acute myeloid leukemia. N Engl J Med 359:651, 2008; author reply, 652-653
-
(2008)
N Engl J Med
, vol.359
, pp. 651
-
-
Buchner, T.1
Berdel, W.E.2
Kienast, J.3
-
14
-
-
84860342455
-
Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia
-
Saber W, Opie S, Rizzo JD, et al: Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 119:3908-3916, 2012
-
(2012)
Blood
, vol.119
, pp. 3908-3916
-
-
Saber, W.1
Opie, S.2
Rizzo, J.D.3
-
15
-
-
58149388069
-
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group
-
Büchner T, Berdel WE, Haferlach C, et al: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27:61-69, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 61-69
-
-
Büchner, T.1
Berdel, W.E.2
Haferlach, C.3
-
16
-
-
33745003472
-
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
-
DOI 10.1200/JCO.2005.04.5013
-
Büchner T, Berdel WE, Schoch C, et al: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480-2489, 2006 (Pubitemid 46655599)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.16
, pp. 2480-2489
-
-
Buchner, T.1
Berdel, W.E.2
Schoch, C.3
Haferlach, T.4
Serve, H.L.5
Kienast, J.6
Schnittger, S.7
Kern, W.8
Tchinda, J.9
Reichle, A.10
Lengfelder, E.11
Staib, P.12
Ludwig, W.-D.13
Aul, C.14
Eimermacher, H.15
Balleisen, L.16
Sauerland, M.-C.17
Heinecke, A.18
Wormann, B.19
Hiddemann, W.20
more..
-
17
-
-
1542753653
-
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group
-
DOI 10.1200/JCO.2003.02.133
-
Büchner T, Hiddemann W, Berdel WE, et al: 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): A randomized trial of the German AML Cooperative Group. J Clin Oncol 21:4496-4504, 2003 (Pubitemid 46603514)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.24
, pp. 4496-4504
-
-
Buchner, T.1
Hiddemann, W.2
Berdel, W.E.3
Wormann, B.4
Schoch, C.5
Fonatsch, C.6
Loffler, H.7
Haferlach, T.8
Ludwig, W.-D.9
Maschmeyer, G.10
Staib, P.11
Aul, C.12
Gruneisen, A.13
Lengfelder, E.14
Frickhofen, N.15
Kern, W.16
Serve, H.L.17
Mesters, R.M.18
Sauerland, M.C.19
Heinecke, A.20
more..
-
18
-
-
0037217950
-
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 trial
-
DOI 10.1182/blood-2002-02-0532
-
Kern W, Haferlach T, Schoch C, et al: Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 101:64-70, 2003 (Pubitemid 36025888)
-
(2003)
Blood
, vol.101
, Issue.1
, pp. 64-70
-
-
Kern, W.1
Haferlach, T.2
Schoch, C.3
Loffler, H.4
Gassmann, W.5
Heinecke, A.6
Sauerland, M.C.7
Berdel, W.8
Buchner, T.9
Hiddemann, W.10
-
19
-
-
84055218304
-
Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management
-
Estey EH: Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87:89-99, 2012
-
(2012)
Am J Hematol
, vol.87
, pp. 89-99
-
-
Estey, E.H.1
-
20
-
-
84876087623
-
Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission
-
Burnett AK, Goldstone A, Hills RK, et al: Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 31:1293-1301, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 1293-1301
-
-
Burnett, A.K.1
Goldstone, A.2
Hills, R.K.3
-
21
-
-
78649429727
-
Reduced mortality after allogeneic hematopoietic-cell transplantation
-
Gooley TA, Chien JW, Pergam SA, et al: Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363:2091-2101, 2010
-
(2010)
N Engl J Med
, vol.363
, pp. 2091-2101
-
-
Gooley, T.A.1
Chien, J.W.2
Pergam, S.A.3
-
22
-
-
84866894134
-
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: A prospective, open-label randomised phase 3 trial
-
Bornhäuser M, Kienast J, Trenschel R, et al: Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: A prospective, open-label randomised phase 3 trial. Lancet Oncol 13:1035-1044, 2012
-
(2012)
Lancet Oncol
, vol.13
, pp. 1035-1044
-
-
Bornhäuser, M.1
Kienast, J.2
Trenschel, R.3
-
23
-
-
77449159028
-
Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
-
Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
-
(2010)
Blood
, vol.115
, pp. 453-474
-
-
Döhner, H.1
Estey, E.H.2
Amadori, S.3
-
24
-
-
0037097716
-
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis
-
DOI 10.1182/blood.V99.12.4326
-
Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002 (Pubitemid 34627197)
-
(2002)
Blood
, vol.99
, Issue.12
, pp. 4326-4335
-
-
Thiede, C.1
Steudel, C.2
Mohr, B.3
Schaich, M.4
Schakel, U.5
Platzbecker, U.6
Wermke, M.7
Bornhauser, M.8
Ritter, M.9
Neubauer, A.10
Ehninger, G.11
Illmer, T.12
-
25
-
-
28444449081
-
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
-
DOI 10.1182/blood-2005-06-2248
-
Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005 (Pubitemid 41739006)
-
(2005)
Blood
, vol.106
, Issue.12
, pp. 3733-3739
-
-
Schnittger, S.1
Schoch, C.2
Kern, W.3
Mecucci, C.4
Tschulik, C.5
Martelli, M.F.6
Haferlach, T.7
Hiddemann, W.8
Falini, B.9
-
26
-
-
28444473100
-
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations
-
DOI 10.1182/blood-2005-05-2164
-
Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005 (Pubitemid 41739007)
-
(2005)
Blood
, vol.106
, Issue.12
, pp. 3740-3746
-
-
Dohner, K.1
Schlenk, R.F.2
Habdank, M.3
Scholl, C.4
Rucker, F.G.5
Corbacioglu, A.6
Bullinger, L.7
Frohling, S.8
Dohner, H.9
-
27
-
-
0037108111
-
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA)
-
Preudhomme C, Sagot C, Boissel N, et al: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723, 2002
-
(2002)
Blood
, vol.100
, pp. 2717-2723
-
-
Preudhomme, C.1
Sagot, C.2
Boissel, N.3
-
28
-
-
77449146413
-
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome
-
Dufour A, Schneider F, Metzeler KH, et al: Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 28:570-577, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 570-577
-
-
Dufour, A.1
Schneider, F.2
Metzeler, K.H.3
-
29
-
-
84905682636
-
Allogeneic stem cell transplantation confers a favorable outcome in patients with NPM1 positive acute myeloid leukemia: Results from a donor vs. No-donor analysis of 309 patients treated in the SAL AML-203 trial
-
abstr 493
-
Rollig C, Bornhauser M, Thiede C, et al: Allogeneic stem cell transplantation confers a favorable outcome in patients with NPM1 positive acute myeloid leukemia: Results from a donor vs. no-donor analysis of 309 patients treated in the SAL AML-203 trial. Blood 118, 2011 (abstr 493)
-
(2011)
Blood
, vol.118
-
-
Rollig, C.1
Bornhauser, M.2
Thiede, C.3
|